Overview
NICE is unable to make a recommendation on daratumumab (Darzalex) with pomalidomide (Imnovid) and dexamethasone for treating relapsed or refractory multiple myeloma because Janssen did not provide an evidence submission.
Last reviewed: 22 September 2021
Next review: We will review this decision if the company decides to make a submission.